Competitive Advantages:
AF target specific, More effective than existing channel blocking methods, Potent blocker of IKACh channel, Safer pharmacotherapeutic profile.
Described herein are peptibodies that can contain a TertiapinQ peptide, formulations thereof, and uses thereof. In some embodiments, the peptibody can include a first monomer and a second monomer, wherein each monomer can include an Fe polypeptide, a first TertiapinQ peptide, wherein the N-terminus of the first TertiapinQ peptide can be linked to the C-terminus of the Fe polypeptide via a first linker, and wherein the first monomer and the second monomer can be attached via a disulfide bridge between the Fe polypeptide of the first monomer and the Fe polypeptide of the second monomer. The compositions and formulations thereof can be used to treat atrial fibrillation.Inventors at USF have bioengineered a peptibody which has proven to be a potent blocker of the acetylcholine activated inward rectifier current (IKACh). IKACh plays an important role in chronic AF, making this potassium current a compelling therapeutic target. The bioengineered peptibody developed is a fusion protein between previously studied anti-IKACh peptides, TertiapinQ and human IgG1 Fc. Both Tertiapin Q and human IgF1 have been studied individually in past research, but the fusion protein has been shown to be a more potent channel blocker than the aforementioned peptides separately. USF researchers have collected solid data from laboratory animal testing of mice and sheep models that shows substantial recover of heart rate after treatment with the fusion protein.
Brochure
